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A b s t r a c t  
Present study involves the formulation and evaluation of floating tablets Ranitidine hydrochloride by 
direct compression method by using HPMC K4M, HPMC K100M as a synthetic polymers and Gellan 
Gum (low acyl) as a natural polymer with addition of sodium bicarbonate and citric acid as 
effervescent agent. The physicochemical compatibility of the drug and the polymers was studied by 
infrared spectroscopy and differential scanning calorimetry. The results suggested that drug and the 
polymers were physicochemically compatible with each other. The effect of synthetic and natural 
polymers on the drug release and floating properties of tablet were investigated. Formulation was 
optimized on the basis of pre compression and post compression parameters, floating lag time, total 
floating time and in vitro drug release study was carried out. The floating lag time, dissolution studies 
indicated that formulation F11 with drug: polymer ratio 5:4 exhibited sustained release of drug and 
followed Korsemeyer Peppas kinetics. Natural polymer (Gellan Gum) showed better results for 
sustained drug release properties than synthetic polymer. The floating lag time was found to be 
increase significantly with increase in concentration of polymer and drug release was found to 
decrease with increase concentration of polymers. 
Keywords: Floating drug delivery, Natural polymers, Synthetic polymers, Ranitidine Hydrochloride. 
Introduction 
Oral route is the most common and convenient route used for the 
administration of drug. The dosage form given through the oral 
route is more flexible to design as compared to other routes of 
administration [1]. Gastro retentive drug delivery system is the 
system in which the gastric residence time is prolonged thereby 
targeting the site specific drug release in the upper gastrointestinal 
tract for local as well as systemic effects [2, 3]. This dosage form 
remains in gastric region for longer period of time. The delivery of 
drugs by oral route is the most preferred route for drug delivery as 
it has various advantages such as ease of administration, patient 
compliance, low cost therapy and flexibility in formulation [4]. In 
spite of these advantages, this system has limited success in case 
of drugs with a poor absorption window throughout the 
gastrointestinal tract (GIT). Modifying the GI transit time is most 
challenging in the development of oral controlled drug delivery 
system. This is because gastric emptying is dependent on the 
dosage form and fasted state of the stomach. Normal GRT (Gastric 
residence time) ranges in between 5 min ă 2 hours [5]. In the 
fasted state the activity is governed by MMC (Migrating Myoelectric 
Complex). This MMC is also termed as interdigestive myoelectric 
cycle and hence the transit of dosage forms [6]. Ranitidine 
hydrochloride (Ranitidine HCl) is a histamine H2-receptor 
antagonist. It is widely prescribed in active duodenal ulcers, gastric 
ulcers, Zollinger-Ellison syndrome, gastro esophageal reflux 
disease, and erosive esophagitis. A conventional dose of 
Ranitidine HCl (150 mg) can inhibit gastric acid secretion up to five 
hours, but not up to long time. While 300 mg dose of Ranitidine 
HCl leads to plasma fluctuations; thus a sustained release dosage 
form of Ranitidine hydrochloride is most efficient. Ranitidine HCl 
has short biological half-life (~2.5 ă 3 hours) also favors 
development of a sustained release formulation.  
Ranitidine HCl is BCS class III drug [7, 9] and it absorbed only in 
the proximal part of the small intestine and has about 50% absolute 
bioavailability. Moreover, poor bioavailability of ranitidine from the 
colon is due to colonic metabolism of Ranitidine [8]. The gastro 
retentive drug delivery systems can be retained in the stomach and 
assist in improving the oral sustained delivery of drugs that have an 
absorption window in a particular region of the gastrointestinal 
tract. These systems help in continuously releasing the drug before 
it reaches the absorption window, thus ensuring optimal 
bioavailability.  
The main objective of this study was to formulate and evaluate 
floating effervescent tablet of Ranitidine HCl. The tablets were 
formulated by using synthetic polymer, Hydroxylpropylmethyl 
cellulose (HPMC) K4M and HPMC K100 M and natural polymer 
Gellan Gum (low acyl). 
Materials And Methods 
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Materials 
Ranitidine HCl was obtained as a gift sample from Markson 
Pharma, Goa. HPMC K4M and HPMC K100M were purchased 
from Rajesh Chemicals, Mumbai. Gellan Gum (Low Acyl) was 
received as a gift sample from CP Kelco, Mumbai. All other 
excipients used were of an analytical grade. 
Methods 
Preparation and evaluation of Dry Mixture 
The floating tablets of Ranitidine HCl were prepared by direct 
compression method by using uniform blend of powder mixture. 
For this purpose, all the ingredients were weighed accurately. Then 
all the ingredients (except magnesium stearate and talc) were 
mixed properly and the passed through sieve no 80. Then all the 
ingredients were blended uniformly and finally magnesium stearate 
and talc were added to the mixture as post lubricant and mixed 
uniformly. 
The prepared dry mixture was evaluated for micromeritic properties 
including bulk density, tapped density and compressibility index 
parameters.  
Preparation of Ranitidine Hydrochloride Floating Tablets
 
Table 1: Composition of floating tablet formulation of Ranitidine HCl.  
 
Floating tablets of Ranitidine HCl producing effervescence were 
prepared by direct compression method, using varying 
concentrations of different grades of polymers (HPMC K4 M and 
HPMC K100M and Gellan Gum) with sodium bicarbonate and citric 
acid. All the ingredients were weighed accurately and passed 
through sieve no 80. Then, (except Magnesium stearate and talc) 
all other ingredients were blended uniformly using glass mortar and 
pestle. After sufficient mixing of drug as well as other components, 
Talc and magnesium stearate were added, as post lubricant. The 
total weights of the tablets were kept constant for all formulations 
around 400 mg. Tablets were prepared by using  a single punch 
tabletting  machine (Hilab Chemicals, Mumbai, India) with 13 mm 
punches. The different batches of formulation were prepared as 
shown in table 1. 
Characterization of Ranitidine HCl and polymers 
FTIR analysis 
Infrared spectrum of Ranitidine HCl was determined on Fourier 
Transform Infrared spectrophotometer using KBr dispersion 
method. The base line correction was done using dried potassium 
bromide. Then the spectrum of dried mixture of drug and 
potassium bromide was run [10]. Infrared absorption spectrum of 
Ranitidine HCl, Polymers and physical mixture of Ranitidine HCl 
and Polymers was carried out to determine chemical interaction 
between drug and polymer. 
Differential scanning calorimetry 
Differential scanning calorimetry (DSC) studies were carried out 
using Mettle-Toledo DSC 821 instrument. Indium and zinc 
standards were used to calibrate the DSC temperature and 
enthalpy scale. The powdered samples (5 mg) are hermetically 
sealed in aluminum crucibles and heated at a constant rate of 
10ĈC/min over a temperature range of 25ă250ĈC. Inert atmosphere 
was maintained by purging nitrogen gas at flow rate of 30 mL/min. 
results were obtained in triplicates for each sample. 
Evaluation of Tablet Formulation. 
Hardness and Friability 
The hardness of the tablet was determined by using Pfizer 
hardness tester [11]. The friability of tablets was determined using 
Roche Friabilator. Twenty previously weighed tablets were rotated 
at 25 rpm for four minutes. The tablets were dedusted and re-
weighed to calculate the percentage of friability. [11, 12].  
Thickness 
The thickness in millimeters (mm) was measured individually for 10 
pre weighed tablets by using Vernier Callipers. The average 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15
Ranitidine HCL 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150
HPMC K4M 50 100 150 - - - 50 100 50 - - - 100 100 100
HPMC K100M - - - 50 100 150 50 50 100 100 100 100 - - -
Gellan Gum - - - - - - - - - 10 20 30 10 20 30
Sodium bicarbonate 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50
Citric acid 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
PVP - - - - - - - - - 10 10 10 10 10 10
Lactose 125 75 25 125 75 25 75 25 25 55 45 35 55 45 35
Magnesium Stearate 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Talc 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
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thickness and standard deviation were reported. The results were 
as shown in table 4. 
Weight variation 
Twenty tablets were selected randomly from each batch and 
average weighed individually. The weight of individual tablet 
compared with the average weight.  
Drug Content Estimation 
Ten tablets were randomly sampled from each formulation batch, 
finely powdered and individually estimated for the drug content 
after suitable dilution, using UV-VIS spectrophotometer (UV-1600, 
Shimadzu) at 314 nm [13]. 
In vitro buoyancy studies 
The in vitro buoyancy was determined by floating lag time and total 
floating time. The study was performed in 100 ml beaker containing 
simulated gastric fluid, pH 1.2 as per USP. The time taken by the 
tablet to rise to the surface and float was taken as floating lag 
time[FLT] and the duration for which the dosage form constantly 
remained on the surface of medium was determined as the total 
floating time [TFT] [14,15]. 
Determination of Swelling Index 
The swelling index of the tablet was determined in 0.1N HCl (pH 
1.2) at room temperature. The swollen weight of the tablet was 
determined at predefined time intervals. The swelling index was 
expressed in percentage and is calculated by using following 
formula [16]. The swelling index is shown in figure 3. 
 SI = W1-W0   ï 100 
          W0 
Where, 
W1: weight of tablet at time t 
W0: Initial weight of tablet 
In vitro drug release studies  
The release rate from Ranitidine HCl floating tablets was 
determined using United States Pharmacopeia (USP) dissolution 
testing apparatus II (paddle method) under sink conditions. The 
dissolution medium used was 900 ml of 0.1N HCl solution pH (1.2) 
at 37μ 0.5oC. The stirring speed was 50 rpm. 5 ml of sample was 
withdrawn for every one hour for each formulation. The sample 
were diluted suitably and filtered. The required dilutions were made 
and the solution was analyzed for the drug content by using UV 
spectrophotometer (Shimadzu UV -1600) at λ max 314 nm. From 
the above readings the percentage drug release was calculated 
and this was plotted against function of time to study the pattern of 
drug release [13].  
Stability studies 
Stability studies were carried out for optimized formulation (F11) 
according to the International Conference on Harmonization (ICH) 
guidelines. The samples were stored in closed HDPE bottles along 
with 1 g desiccant at temperature 40μ2oC and 75μ5 % Relative 
Humidity for 3 months. Samples were withdrawn after 1, 2, and 3 
months of intervals and were evaluated for drug content, floating 
lag time and in vitro percentage drug release [17].  
Results And Discussion 
FTIR analysis 
FTIR study of the drug (Ranitidine HCl), Polymers (HPMC K4M, 
Gallen gum and HPMC K100M) and physical mixture of drug and 
Polymer were characterized by FTIR spectra, using KBR pellets. It 
was found that the spectra and value of sample Ranitidine HCl and 
polymers were match with official standards. No change occurred 
in peak pattern of FTIR spectra of pure drug, pure excipients in 
physical mixture of drug and polymers shown in figure 1. Hence 
drug and polymers were found to be compatible with each other.
 
Figure 1: FTIR Compatibility study of drug and excipients. 
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Table 3: Interpretation of FT-IR Spectrum of drug and polymer combination. 
 

























2 Combination of 
Polymer and 
Ranitidine HCL 
3451.64 O-H stretching 
2923.97 C-H stretching 






Differential Scanning Calorimetry 
The DSC thermogram of pure Ranitidine HCl has shown a sharp 
endotherm at 148.32ĈC corresponding to its melting point. This 
sharp endothermic peak signifies crystalline nature of pure 
Ranitidine HCl. While optimized batch (F11) showed the 
endothermic peak at139.39ĈC with the loss of its sharp appearance 
and other peak of an excipients shown in figure 2. The broadening 
and shifting of peak towards the left side shows the entrapment of 
drug into formulation. 
 
 
Figure 2: DSC thermogram of Ranitidine HCl and optimized formulation (F11). 
 
Evaluation of physical properties of pre-compressed 
granules 
The physical properties like Compressibility index (CI), Angle of  
 
 
repose and Hausners ratio were calculated and tabulated in table 
2. The results of the physical properties of many of the blends were 
in the limits and comply with the standards. 
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       Table 2: Evaluation of Dry Mixture. 
 









F1 27.74μ0.21 0.370μ0.02 0.465μ0.038 1.22μ0.14 18.50μ0.48
F2 22.87μ0.56 0.344μ0.05 0.408μ0.018 1.18μ0.30 15.68μ0.12
F3 24.74μ0.0.51 0.322μ0.08 0.400μ0.023 1.24μ0.36 19.50μ0.18
F4 25.40μ0.12 0.363μ0.05 0.444μ0.023 1.22μ0.12 18.24μ0.39
F5 21.99μ0.54 0.333μ0.06 0.400μ0.019 1.20μ0.13 16.75μ0.51
F6 23.02μ0.21 0.317μ0.09 0.400μ0.046 1.26μ0.006 20.75μ0.14
F7 23.26μ0.66 0.384μ0.02 0.454μ0.041 1.18μ0.11 15.41μ0.16
F8 25.68μ0.43 0.363μ0.06 0.434μ0.029 1.19μ0.24 14.58μ0.27
F9 24.65μ0.20 0.357μ0.08 0.434μ0.052 1.21μ0.30 17.74μ0.34
F10 25.26μ0.42 0.408μ0.04 0.487μ0.043 1.19μ0.10 16.22μ0.23
F11 24.93μ0.33 0.400μ0.02 0.487μ0.024 1.21μ0.31 17.86μ0.34
F12 22.39μ0.61 0.392μ0.05 0.500μ0.015 1.27μ0.27 21.06μ0.12
F13 24.18μ0.30 0.392μ0.02 0.465μ0.035 1.18μ0.12 15.69μ0.37
F14 25.96μ0.22 0.384μ0.02 0.465μ0.046 1.21μ0.16 17.41μ0.21
F15 26.24μ0.57 0.377μ0.06 0.476μ0.010 1.26μ0.25 20.79μ0.24
(Mean μ S.D., n = 3). 
 
Evaluation of physicochemical properties of tablets 
The physical characteristics of tablets such as tablet hardness, 
friability, weight variation and drug content for all the formulations 
were determined. The hardness of the tablets of all formulations 
passed the test as per the acceptance criteria. The friability and 
weight variation was found to be within the limits specified in 
pharmacopoeia. The percentage drug content of all the 
formulations complies with official specifications. The values are 
given in table 4. 
    



















F1 4.8μ0.23 4.0μ0.03 13μ0.02 0.58μ0.02 98.35μ0.12 0.400μ0.80 28 4
F2 5.2μ0.05 4.1μ0.01 13μ0.01 0.75μ0.03 98.18μ0.58 0.400μ1.25 24 8
F3 5.4μ0.32 4.2μ0.05 13μ0.04 0.90μ0.07 97.65μ0.72 0.400μ1.20 35 12
F4 4.9μ0.16 4.0μ0.04 13μ0.02 0.54μ0.05 97.35μ0.18 0.400μ0.90 32 4
F5 5.1μ0.20 4.1μ0.02 13μ0.01 0.45μ0.02 98.64μ0.96 0.400μ1.26 24 10
F6 5.5μ0.32 4.2μ0.08 13μ0.05 0.64μ0.10 98.77μ0.78 0.400μ1.22 42 12
F7 5.1μ0.34 4.0μ0.01 13μ0.02 0.58μ0.10 97.84μ0.32 0.400μ1.48 34 8
F8 5.5μ0.12 4.2μ0.04 13μ0.05 0.64μ0.04 98.36μ0.98 0.400μ1.30 30 10
F9 5.5μ0.25 4.2μ0.05 13μ0.04 0.68μ0.06 98.72μ0.14 0.400μ1.32 30 10
F10 5.2μ0.24 4.0μ0.01 13μ0.02 0.50μ0.02 98.10μ0.78 0.400μ1.20 28 12 
F11 5.2μ0.15 4.0μ0.02 13μ0.02 0.54μ0.04 98.27μ0.14 0.400μ1.05 30 12 
F12 5.5μ0.10 4.1μ0.02 13μ0.02 0.48μ0.04 98.69μ0.34 0.400μ1.10 38 12 
F13 5.0μ0.26 4.0μ0.02 13μ0.02 0.48μ0.06 98.98μ0.74 0.400μ1.32 30 10
F14 5.2μ0.18 4.0μ0.02 13μ0.02 0.52μ0.04 98.34μ0.88 0.400μ1.44 33 10
F15 5.6μ0.04 4.0μ0.04 13μ0.01 0.46μ0.08 97.48μ0.32 0.400μ1.06 37 10
(Mean μ S.D., n = 3). 
 
In vitro buoyancy studies 
All the formulations were prepared by effervescent approach .In 
vitro Buoyancy and Total floating time were determined by using 
100 ml beaker containing 0.1N HCl as shown in figure 3,  the gas 
generated is trapped  and protected  within the gel formed by 
hydration of polymers thus decreasing density of the tablet . As the 
density of tablet falls <1, the tablet become buoyant. The result 
showed that the floating lag time was in range of 24 sec to 38 Sec 
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and total floating time in range of 4 hours to 12 hours. (Table 4) 
Both floating lag time and total floating time increases with increase 
in concentration of polymers[18].Total floating time for the 
formulations containing HPMC K100M with Gallen gum were 




Figure 3: In-Vitro Buoyancy Studies of Ranitidine HCl Floating Tablet (F11). 
 
Swelling index 
The swelling index was calculated with respect to time. As time 
increase, the swelling index was increased, because weight gain 
by tablet was increased proportionally with rate of hydration. Later 
on, it decreased gradually due to dissolution of outermost gelled 
layer of tablet into dissolution medium. The direct relationship was 
observed between swelling index and HPMC concentration and as 
HPMC concentration increase, swelling index was increased. 
Results are shown in figure 4 and figure 5. 
 
 
Figure 4: Swelling index of F1-F9 Formulations. 








Figure 5: Swelling index of F10-F15 Formulations. 
 
In vitro dissolution studies 
All the formulations were subjected to in vitro dissolution studies 
using USP dissolution testing apparatus II (paddle method) in 900 
ml of 0.1N HCl for 12h. The formulations F1,F2,F3, containing 
different concentration of HPMC K4M shows that the drug release 
vary from 85.84μ2.12% - 97.36μ1.73% while formulation F4, F5, 
F6, containing different concentration of HPMC K100 M shows that 
the drug release vary from 82.52μ1.27% - 95.71μ1.12% within 12h. 
The formulation F7, F8, F9 containing the combination of polymers 
HPMC K4M and HPMC K100M the proportion of polymers are 
taken in ratio 1:1, 2:1 and 1:2 respectively, shows that the drug 
release vary from 92.48μ1.32% - 95.22μ1.85% while formulation 
F10, F11, F12 containing combination of polymers Gellan Gum and 
HPMC K100M shows that the drug release vary from 89.21μ2.12% 
- 92.65μ1.73% within 12h. The formulation F13, F14, F15 
containing combination of polymers Gellan Gum and HPMC K4M 
shows that the drug release vary 88.87μ2.12% - 94.29μ1.73%. 
There is increase in floating lag time as the concentration of Gellan 
gum is increased. Faster drug release from batch containing 
HPMC K4M was probably due to faster diffusion of soluble drug out 
of the matrix. Water soluble polymer forms pores for entry of 
solvent molecules [19, 20]. At higher polymer loading, the viscosity 
of the gel matrix is increased which results in a decrease in the 
effective diffusion coefficient of the drug and hence decreased drug 
release into the dissolution medium so decrease in drug release 
rate [21]. The results from in-vitro buoyancy studies, in-vitro drug 
release were found that the optimized formulation F11 showed 
slow and sustained release of ranitidine hydrochloride over a 
period of 12 hours over other batches. Drug release kinetics study 
shows, the best fitting model for optimized batch is Korsemeyer 
Peppas Model and the r2 value is 0.9897 shown in table 5. 
From the in vitro dissolution study it was concluded that release 
from the tablet matrix is largely dependent on the polymer swelling, 
drug diffusion and matrix erosion. Large concentration of high 
viscosity polymer induces the formation of strong viscous gel layer 
that slowed down the rate of water diffusion into the tablet matrix, 
which may result in the retardation or decreases the drug release. 




Figure 6: Comparison of in vitro dissolution profile of F1-F9. 
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Figure 7: Comparison of in vitro dissolution profile of F10-F15. 
 
Table 5: Drug Release Kinetics of Ranitidine HCl Floating tablets. 
 
Batch Code Zero order First order Higuchi Hixson- crowel Korsemeyer Peppas Best Fitting Model 
F1 0.9744 0.9965 0.9996 0.9996 0.9999 Peppas 
F2 0.9935 0.8762 0.9598 0.9554 0.9975 Peppas 
F3 0.9068 0.9861 0.9971 0.9839 0.9982 Peppas 
F4 0.9763 0.9973 0.9993 0.9995 0.9997 Peppas 
F5 0.9901 0.8947 0.9498 0.9570 0.9783 Zero order 
F6 0.9581 0.9784 0.9769 0.9876 0.9770 Hixson crowel 
F7 0.9885 0.9609 0.9655 0.9902 0.9986 Peppas 
F8 0.9581 0.9544 0.9873 0.9912 0.9981 Peppas 
F9 0.9742 0.9263 0.9695 0.9707 0.9882 Peppas 
F10 0.9820 0.9549 0.9693 0.9873 0.9928 Peppas 
F11 0.9854 0.9550 0.9576 0.9812 0.9897 Peppas 
F12 0.9244 0.9956 0.9925 0.9927 0.9950 First order 
F13 0.9622 0.9479 0.9843 0.9857 0.9930 Peppas 
F14 0.9643 0.9638 0.9837 0.9898 0.9934 Peppas 
F15 0.9756 0.9703 0.9773 0.9918 0.9957 Peppas 
 
Stability studies 
Stability studies were carried out as per ICH guidelines and results 
were represented in Table 6. Drug content and drug release revels 
that after 3 months of stability studies there was no significant 
difference in Drug content, floating lag time and drug release 
(figure 8). 
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Table 6: Evaluation of optimized formulation (F11) after stability period. 
Parameters Period  
Before After 30 days After 60 days After 90 days 
Floating lag time (s) 30 30 30 31 
Drug content 98.27μ0.14 98.13μ0.17 98.02μ0.57 97.95μ0.89 
Drug release after 12 h 89.212 89.532 89.745 90.071 
 
 
Figure 8: % Drug Release study after Stability Study of optimized formulation (F11). 
 
Conclusion 
From the above study it was concluded that, HPMC K4M, HPMC 
K100M and Gellan Gum are compatible with Ranitidine 
hydrochloride based on the results obtained from compatibility 
studies and hence they are suitable for floating tablets of Ranitidine 
hydrochloride. From the in-vitro buoyancy studies it was concluded 
that, Gellan gum shows somewhat more floating lag time than 
HPMC K4M and HPMC K100M respectively. The floating lag time 
was found to be significantly increased with increase in 
concentration of polymer. The formulation containing HPMC K4M 
shows greater percentage of drug release as compared to other 
polymers containing formulations. Natural polymer (Gellan gum) 
showed slow and sustained release of ranitidine hydrochloride over 
the synthetic polymers. As the concentration of polymer increases 
the percentage drug release decreases. Finally, it was concluded 
that natural polymer (Gellan Gum) can be successfully used for the 




[1]. Shaji J, Patole V. Protein and peptide 
drug delivery: Oral approaches. Indian 
J Pharm Sci 2008;70:269-277 
[2]. Nayak A, Maji R and Das B. 
Gastroretentive drug delivery system; 
Review. Asian. J. Pharm. Res 2010; 
3, 2-10. 
[3]. Mishra A, Gupta P. Gastro Retentive 
Drug Delivery System: A Review. Int. 
J. Drug Dev. & Res 2012; 4 (4): 28-
39. 
[4]. Chawla G, Gupta P, Koradia V, 
Bansal  AK. Gastroretention- A means 
to address regional variability in 
intestinal drug absorption. 
Pharm.Tech 2003; 27(7): 50-51.     
[5]. Shah SH, Patel JK, Patel NV. 
Stomach specific floating drug 
delivery system: A review. Int J Pharm 
Tech Res 2009; 1:623-633. 
[6]. Wilson CG, Washington N. 
Physiological Pharmaceutics: 
Biological Barriers to Drug Absorption, 
Horwood Ellis, Chichester 1989;47-
70. 




PAGE | 253 |
 
[7]. Brijesh SD, Avani FA, Madhabhai MP, 
Gastroretentive Drug Delivery System 
of     Ranitidine Hydrochloride 
Formulation and Invitro Evaluation; 
Aaps Pharm Sci Tech 2004;5(2):1-6. 
[8]. Abdul WB, Larry FL. Colonic 
Metabolism of Ranitidine, Implications 
For its  Delivery and Absorption; Int J 
Pharm 2001;227:157-165. 
[9]. Description and clinical pharmacology 
of Zantac® Tablets (Ranitidine 
Hydrochloride USP) 56th ed. Medical 
economic company 2002; PhysicianÊs 
Desk reference. 
[10]. Robert MS, Francis XW. Infrared 
Spectrometry. In: Robert M. 
Silverstein. Editors. Spectrometric 
Identification of Organic Compounds. 
6th Ed. John Wiley and Sons. Inc. 
New York: 71-143.  
[11]. Indian pharmacopoeia 2007, 
Ghaziabad, India: Indian 
Pharmacopoeia Commission 2007; 1: 
182-183.  
[12]. Marshall K, Lachman N, Liberman 
HA. The theory and practice of 
industrial pharmacy, 3rd edition. 
Mumbai: Varghese publishing house 
1987;66-69. 
[13]. United States Pharmacopeia and 
National Formulary USP 27ăNF 22; 
The United States Pharmacopeial 
Convention, Inc.:Rockville, MD 
2004;454ă458. 
[14]. Ghosh NS, Ghosh S, Debnath S. 
Formulation Of Immediate Dosage 
Form Of Ranitidine Hydrochloride 
Tablets Using HPMC And Starch 
Acetate Film Former; J Chem Pharm 
Res 2010;2:147-157. 
[15]. Xu Xiaoqiang, Sun Minjie, Zhi Feng, 
Hu Yiqiao. Floating matrix dosage 
form for phenoporlamine 
hydrochloride based on gas forming 
agent: In vitro and in vivo evaluation in 
healthy volunteers; International 
Journal of Pharmaceutics 
2006;310:139ă145. 
[16]. Verma S, Narang N. Development 
And In Vitro Evaluation Of Floating 
Matrix Tablets Of Anti Retroviral Drug; 
Int J Pharm Sci 2011;3:208-211. 
[17]. Cartensen JT. Drug Stability: Principle 
and practice. Second edition, Marcel 
Dekker, New York 1995;538-550. 
[18]. Chen YH, Yaung JF. Alka Seltzer 
fizzing- determination of percent by 
mass of sodium bicarbonate in alka 
seltzer tablets. J Chem Ed 
2002;79:848-850. 
[19]. Patil VS, Gaikwad PD, Bankar VH and 
Pawar SP. Formulation And 
Evaluation of Floating Matrix Tablet of 
Locally Acting H2-Antagonist; Int J of 
Pharm and Tech 2010;2:528-540. 
[20]. Enayatifard R, Saeedi M, Akbari J, 
Tabatabaee YH. Effect of 
hydroxypropyl methylcellulose and 
ethyl cellulose content on release 
profile and kinetics of diltiazem HCl 
from matrices. Trop J Pharm Res 
2009;8:425-432. 
[21]. Dhawan S, Varma M, Sinha VR. High 
molecular weight poly(ethylene oxide) 
ă based drug delivery systems Part I: 
Hydrogels and hydrophilic matrix 
systems. Pharm Technol 2005;29:72-
79. 
 
  
 
 
 
